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The etiology of the major psychotic disorders, including 
schizophrenia and bipolar disorder, remains poorly understood. 
Postmortem brain studies have revealed altered expression of 
multiple mRNAs, affecting neurotransmission, metabolism, myeli-
nation and other functions. Epigenetic mechanisms could be 
involved, because for a limited number of genes, the alterations 
of mRNA levels have been linked to inverse DNA methylation 
changes at sites of the corresponding promoters. However, results 
from independent studies have been inconsistent, and when 
expressed in quantitative terms, disease-related methylation changes 
appear to be comparatively subtle. A recent study identified approx-
imately 100 loci with altered CpG methylation in schizophrenia 
or bipolar disorder, the majority of which were gender-specific. 
Additional work will be necessary to clarify the origin and timing 
of these methylation changes in psychosis and to determine the 
specific cell types affected in the diseased brain.
Aberrations in DNA methylation have been implicated in a wide 
variety of brain disorders. Examples include (1) mental retardation 
syndromes resulting from certain imprinting disorders (example: 
Angelman and Prader-Willi syndromes),1,2 triplet repeat expan-
sions (fragile X syndrome),3,4 mutations in DNA methyltransferase 
encoding genes (ICF syndrome)5 and (2) a subset of gliomas6-9 
and neuroectodermal6,10,11 tumors which show promoter hyper-
methylation of tumor suppressor genes. More recently, however, 
DNA methylation has been studied in the context of a very different 
category of brain malady: the major psychotic disorders, including 
schizophrenia and bipolar disorder, which are defined by delusions, 
hallucinations and mood alterations. While a variety of radiological, 
histological and molecular alterations have been observed in schizo-
phrenic12 and bipolar brain,13 a definitive diagnostic neuropathology 
or molecular phenotype is lacking. The etiologies of these disorders 
are complex, demonstrating concordance rates of less than 70% in 
monozygotic twins, non-Mendelian inheritance patterns and sexual 
dimorphism;14 these features, obviously, provide fertile ground for 
“epigenetic” disease models. Of note, the molecular pathology of 
the major psychotic disorders is thought to involve alterations in 
gene expression, including a downregulation of transcripts involved 
in cellular metabolism,15-17 inhibitory neurotransmission18 and 
myelination and other oligodendrocyte functions.19,20 Therefore, it 
is tempting to speculate that at least some of these transcriptional 
defects could be due to aberrant increases in CpG methylation and 
repressive chromatin remodeling at 5' regulatory sequences. However, 
to date, DNA methylation has only been assayed for a small number 
of genes (namely, REELIN,21-24 COMT,25-27 DRD228 and SOX1029) 
in postmortem brain of subjects diagnosed with schizophrenia or 
other major psychoses.
Recently, Mill and colleagues published the first comprehensive 
methylation study of major psychosis,30 in which they assayed meth-
ylation at approximately 7,800 loci—primarily within CpG islands 
of gene promoter regions—in frontal cortex of a comparatively 
large set of postmortem brain samples (35 schizophrenia, 35 bipolar 
and 35 control subjects). Based on Figure 2 of Mill et al., approxi-
mately 100 loci demonstrated significant disease-related methylation 
changes. Interestingly, a subset of the loci that were hypermethylated 
showed altered gene expression in previous studies employing some 
of the same brain samples studied by Mill et al., with approximately 
an equal portion of up and downregulated transcripts. That schizo-
phrenia and bipolar disorder showed methylation changes of similar 
magnitude and direction for a number of loci resonates with some 
of the clinical, genetic and neurochemical features common to both 
disorders.31 Strikingly, the list of genes showing altered methylation 
in Mill et al., includes at least one locus, DYSBINDIN, which confers 
genetic risk for psychosis.32-34 This is interesting, because informa-
tion regarding interactions between sequence polymorphisms and 
epigenetic modifications in human brain is available only for very 
few psychosis genes, including BDNF,30 GAD135 and 5-HT2A.36
Perhaps one of the most intriguing discoveries by Mill et al.,30 
was the finding that the vast majority of disease-related DNA meth-
ylation changes differentially affected male and female patients. At 
present, straightforward explanations for this puzzling phenomenon 
are lacking because the genes involved are located on autosomes and, 
until now, not known to show sex-specific regulation. It remains to 
be determined whether or not these loci are differentially methyl-
ated or show monoallelic expression in normal brain and which, if 
any, of the corresponding gene transcripts are differentially expressed 
in female and male brain. Sex steroids may play a role; estrogen, 
for example, is an important modulator of frontal lobe function 
in females,37,38 and there is ample evidence that the hormone is 
involved in the regulation of chromatin structures, including DNA 
Point of View
DNA methylation changes in schizophrenia and bipolar disorder
Caroline M. Connor1,2 and Schahram Akbarian2,*
1Program in Neurobiology; Graduate School of Biomedical Sciences; 2Department of Psychiatry; University of Massachusetts Medical School; Worcester, Massachusetts USA
Key words: schizophrenia, bipolar disorder, postmortem brain, DNA methylation, epigenetics
*Correspondence to: Schahram Akbarian; Department of Psychiatry; Brudnick 
Neuropsychiatric Research Institute; 303 Belmont Street; University of Massachusetts 
Medical School; Worcester, Massachusetts 01604 USA; Tel.: 508.8562674; 
Fax: 508.8563937; Email: Schahram.akbarian@umassmed.edu
Submitted: 01/28/08; Accepted: 03/19/08
Previously published online as an Epigenetics E-publication: 
http://www.landesbioscience.com/journals/epigenetics/article/5938
www.landesbioscience.com Epigenetics 55
©2
008
 LA
ND
ES 
BIO
SCI
EN
CE.
 DO
 NO
T D
IST
RIB
UT
E.
DNA methylation in psychosis
and histone methylation, at a number of gene promoters.14,39,40 
Furthermore, gender-specific chromatin alterations in schizophrenia 
may extend beyond the level of DNA methylation—both androgens 
and estrogens are known to interact with chromatin remodeling 
complexes14,41-43 and recent evidence suggests that promoter- 
associated histone methylation changes at select GABAergic gene 
loci may be more prominent in female schizophrenia subjects, 
compared to their male counterparts.35 Given the sexual dimor-
phism of schizophrenia and bipolar disorder—including differences 
in rate of occurrence, symptoms and time course—the differential 
methylation changes observed in male and female patients should 
not come as a surprise.
It is noteworthy that absolute methylation differences between 
psychosis and control samples were relatively small in the Mill et 
al. study,30 even for some of the more significant loci (for example, 
17% vs. 25% for WDR18). Therefore, DNA methylation changes in 
psychosis appear to be more subtle compared to those observed in 
brain neoplasia or some of the above-mentioned mental retardation 
syndromes. These features emphasize that DNA methylation analysis 
in psychosis samples is best approached by quantitative methodology, 
for which bisulfite sequencing remains the gold standard.44 Given 
this lack of dramatic methylation changes in schizophrenia or bipolar 
brain, it comes as no surprise that earlier studies reporting positive 
findings (REELIN,21,22 COMT25) were not consistently replicated 
in subsequent work.23,24,26,27,30 Some of these inconsistencies may 
be due differences in methodology, the specific CpG dinucleotides 
assayed, brain regions examined and clinical populations from which 
the postmortem specimens were obtained. Furthermore, it must be 
noted that for these genes, the degree of DNA methylation may not 
necessarily correlate with functional consequences (i.e., decrease in 
mRNA transcript levels); rather, the specific location of the methy-
lated CpG dinucleotide—for example, within a transcription factor 
binding site—may be more critical for mediating transcriptional 
repression. 
In addition to the overall subtle nature of these psychosis-related 
alterations, the interpretation of DNA methylation studies on post-
mortem brain is complicated by additional factors:
(1) To date, most methylation studies in brain have utilized 
DNA extracted from whole tissue homogenates. This represents a 
major confound, as different cell types are known to possess unique 
methylation patterns and brain tissue is comprised of multiple types 
of neurons, glia and other cells. Moreover, specific sub-populations 
of cells within specific brain regions are thought to be affected 
in the psychotic disorders, such as parvalbumin-immunoreactive 
neurons,45-49 oligodendrocytes50-53 and astrocytes.54-56 Thus, if 
alterations in DNA methylation within specific cell populations do 
indeed play a role in the pathoetiology of psychosis, some meth-
ylation changes may be “diluted”—or even undetectable—due to 
the averaging of methylation signals from a heterogeneous pool of 
cells. Furthermore, neuron-to-glia ratios show considerable varia-
tion during the course of normal maturation and aging.57 This is 
not a trivial point, because there is evidence that, for select gene 
loci, the DNA methylation signal from postmitotic neurons differs 
considerably from tissue homogenate. Specifically, when DNA 
methylation was selectively assayed for neuronal nuclei obtained 
from postmortem human brain, 4/10 loci showed age-related 
methylation changes similar to DNA from tissue homogenate, but 
6/10 loci did not.58
(2) In addition, in vitro studies in cell culture suggest that DNA 
methylation is dynamically regulated—on the scale of minutes to 
hours—in response to DNA methyltransferase inhibitors59,60 and 
depolarization.61 Thus, it will be important to more fully elucidate 
how diverse environmental stimuli impact the regulation of DNA 
methylation in human brain, as these factors could potentially 
result in methylation changes unrelated to disease etiology. Indeed, 
recent studies have demonstrated that the DNA methyltransferases 
and methylation patterns in a variety of tissues, including CNS, are 
influenced by a variety of factors, including social environment,62,63 
ischemia,64 environmental toxins,65-67 nicotine,68 alcohol,69 psycho-
stimulants70,71 and antipsychotic drugs.30,72,73
However, the above-mentioned factors could also play a role in 
the pathogenesis of schizophrenia and bipolar disorder. Thus, it 
will be important to explore both the origin and timing of DNA 
methylation changes in psychosis whether they arise from stochastic 
events during embryogenesis, are secondary effects of psychosis in 
the patient (or even in an affected parent), or reflect exposure to 
different environmental stimuli during subsequent development, 
maturation and aging remains to be determined. The latter hypoth-
esis gains credence from work by Fraga et al., (2005)74 which shows 
that methylation patterns of monozygotic twins become increas-
ingly different with age; furthermore, twins who were raised apart 
demonstrated greater differences in DNA methylation patterns than 
those raised together. In addition to environmental influences, accu-
mulating evidence suggests that epigenetic marks can be inherited 
across multiple generations,75-77 providing an alternative explanation 
for the aggregation of schizophrenia and bipolar disorder in families. 
However, to date, evidence for DNA methylation changes in germ 
cells of individuals diagnosed with major psychosis is lacking.30
Therefore, while important issues remain to be resolved, including 
the origin of methylation changes in schizophrenia and bipolar 
disorder, ante- and postmortem confounds, and cellular heteroge-
neity of brain tissue, one can expect that epigenetic studies on human 
brain, such as the one undertaken by Mill et al.,30 will significantly 
advance our understanding of the molecular pathology underlying 
complex psychiatric disorders.
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